Suntharalingam Kogularamanan, Lin Wei, Johnstone Timothy C, Bruno Peter M, Zheng Yao-Rong, Hemann Michael T, Lippard Stephen J
Department of Chemistry and ‡The Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology , Cambridge, Massachusetts 02139, United States.
J Am Chem Soc. 2014 Oct 15;136(41):14413-6. doi: 10.1021/ja508808v. Epub 2014 Oct 6.
The effect of a newly developed osmium(VI) nitrido complex, 1, on breast cancer stem cells (CSCs) is reported. The complex displays selective toxicity for HMLER breast cancer cells enriched with CD44-positive, CSC-like cells over the same cells having reduced CSC character. Remarkably, 1 also reduces the proportion of CSCs within a heterogeneous breast cancer cell population and irreversibly inhibits the formation of free-floating mammospheres to an extent similar to that of salinomycin, a natural product that targets CSCs. Detailed mechanistic studies reveal that in breast cancer cells 1 induces DNA damage and endoplasmic reticulum stress, the latter being responsible for the CSC selectivity. The anti-CSC properties of 1 provide a strong impetus for the development of new metal-based compounds to target CSCs and to treat chemotherapy-resistant and relapsed tumors.
据报道,一种新开发的锇(VI)氮化物配合物1对乳腺癌干细胞(CSCs)有影响。该配合物对富含CD44阳性、具有CSC样细胞特征的HMLER乳腺癌细胞显示出选择性毒性,而对CSC特征降低的相同细胞则无此毒性。值得注意的是,1还降低了异质性乳腺癌细胞群体中CSCs的比例,并不可逆地抑制了自由漂浮的乳腺球的形成,其抑制程度与靶向CSCs的天然产物沙林霉素相似。详细的机制研究表明,在乳腺癌细胞中,1诱导DNA损伤和内质网应激,后者是CSC选择性的原因。1的抗CSC特性为开发靶向CSCs的新型金属基化合物以及治疗化疗耐药和复发性肿瘤提供了强大动力。